GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

GSK PLC (GSK) reports a robust 17% increase in specialty medicines sales, while vaccine sales face a 6% decline, impacting ...

In its update, GSK reported a 17% rise in specialty medicines across its HIV, cancer, and respiratory business to £2.93 ...

A groundbreaking new malaria vaccine that could be three times more effective than existing jabs is under development by ...

GSK announced on Thursday that its monoclonal antibody ‘Nucala’, or mepolizumab, delivered a statistically significant and ...

UK pharma major GSK (LSE: GSK) has published results from its Phase III MATINEE trial evaluating Nucala (mepolizumab) in ...

GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American depositary share (ADS), which beat the Zacks ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...

GSK's Q1 2025 earnings will reveal progress in specialty medicines amid regulatory headwinds. Learn what to watch when the ...

GSK is 'well positioned' to deal with the potential implications of any new US tariffs on pharma imports, the group said on ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe ...

Q1 2025 Earnings Call Transcript April 30, 2025 GSK plc beats earnings expectations. Reported EPS is $1.13, expectations were ...